Patent ID: 9582637
Date: 2017-02-28
CPC Classifications: G16B,G16H,Y02A

Claim:
1. In a virtual cell system that automates design synthesis, test and simulation according to automated perturbation or mutagenesis stimulation by a controller of virtual cell system biology of TPMT enzyme activity that automatically uses clinical trial FDA pharmacogenomic submission data including genotype, haplotype, phenotype, and system biology pathways that model and simulate networks and pathways based on pair-wise labeled relationships between proteins, genes, or RNA transcripts associated with the TPMT enzyme activity in such virtual cell system, whereby such virtual cell perturbation or mutagenesis stimulation by the controller predicts TPMT enzyme activity using automated TPMT simulation according to host drug metabolism, transport, distribution and excretion associated with TPMT enzyme activity simulated by the TPMT virtual cell system, a controller-automated alert method for displaying a pharmaco-genomic mutation message associated with compromised TPMT enzyme activity comprising the steps of: comparing by a virtual cell system that automates design synthesis, test and simulation according to automated perturbation or mutagenesis stimulation by a controller of virtual cell system biology of TPMT enzyme activity that automatically uses clinical trial FDA pharmacogenomic submission data including genotype, haplotype, phenotype, and system biology pathways that model and simulate networks and pathways based on pair-wise labeled relationships between proteins, genes, or RNA transcripts associated with the TPMT enzyme activity in such virtual cell system, whereby such virtual cell perturbation or mutagenesis stimulation by the controller predicts TPMT enzyme activity using automated TPMT simulation according to host drug metabolism, transport, distribution and excretion associated with TPMT enzyme activity simulated by the TPMT virtual cell system, using bioinformatic values recently-measured, and previously-stored which are associated with a host ability to produce thiopurine S-methyltransferease (TPMT) enzyme activity to determine a pharmaco-genomic mutation associated with the host, wherein such comparison by the virtual cell system further employs substantial equivalent value check between recently-measured and previously-stored bioinformatic values, such further comparison being employed iteratively or dynamically in real-time by the controller via multiple or parallel processors to perform the substantial equivalent value check automatically after host exposure to radiation or other carcinogenic source, thereby enabling the controller of the virtual cell system design to synthesize, test and simulate TPMT enzyme activity also according to automated perturbation or mutagenesis stimulation in real-time after the host exposure to radiation or other carcinogenic source; and indicating electronically on a display controller in the virtual cell system that automates design synthesis, test and simulation according to automated perturbation or mutagenesis stimulation by the controller of virtual cell system biology of TPMT enzyme activity that automatically uses clinical trial FDA pharmacogenomic submission data including genotype, haplotype, phenotype, and system biology pathways that model and simulate networks and pathways based on pair-wise labeled relationships between proteins, genes, or RNA transcripts associated with the TPMT enzyme activity in such virtual cell system, whereby such virtual cell perturbation or mutagenesis stimulation by the controller predicts TPMT enzyme activity using automated TPMT simulation according to host drug metabolism, transport, distribution and excretion associated with TPMT enzyme activity simulated by the TPMT virtual cell system, a pharmaco-genomic mutation message indicating whether the host is at risk for 6-MP/azathioprine/thioguanine toxicity, thereby effectively enabling electronic labeling of the pharmaco-genomic mutation message via the electronic display thereof, thereby improving confidence medically to alert pharmaco-genomic mutation being associated with compromised TPMT enzyme activity in order automatically to facilitate tailoring of dosing regimen, and thus minimize concern over drug-induced host complication from 6-MP/azathioprine/thioguanine toxicity, wherein the controller causes the pharmaco-genomic mutation message associated with compromised TPMT enzyme activity to be indicated electronically using a virtual cell system biology data format according to automated perturbation or mutagenesis stimulation using by the controller a TPMT virtual cell system comprising an expert system that automates design synthesis, test and simulation of virtual cell system biology of TPMT enzyme activity, such virtual cell system automatically using the virtual cell system biology data format to enable virtual cell perturbation or mutagenesis stimulation by the controller to predict TPMT enzyme activity using automated TPMT simulation according to host drug metabolism, transport, distribution or excretion associated with TPMT enzyme activity simulated by the TPMT virtual cell system, thereby automatically alerting the pharmaco-genomic mutation associated with compromised TPMT enzyme activity and thus predict such associated behavior according to the host drug metabolism, transport, distribution or excretion, wherein the pharmaco-genomic mutation message further indicates the pharmaco-genomic mutation associated with compromised TPMT enzyme activity according to the comparison by the virtual cell system that further employs substantial equivalent value check between recently-measured previously-stored bioinformatic values, such further comparison being employed iteratively or dynamically in real-time by the controller via multiple or parallel processors to perform the substantial equivalent value check automatically after host exposure to radiation or other carcinogenic source, thereby enabling the controller of the virtual cell system design to synthesize, test and simulate TPMT enzyme activity also according to automated perturbation or mutagenesis stimulation in real-time after the host exposure to radiation or other carcinogenic source.